31st Mar 2021 06:57
RTW Venture Fund Ltd - investment company focused on the life sciences sector - Co-Leads USD152 million series B round in Pyxis Oncology Inc. This round brings Pyxis' total funding to USD174 million. Pyxis is a privately held biotechnology company building a portfolio of biologics, including antibody-drug conjugates and immunotherapies, to help patients with difficult-to-treat cancers.
"Pyxis will use the proceeds from the financing round to advance its differentiated portfolio of ADCs, a growing class of therapies that deliver highly potent targeted treatments directly to cancer cells, including PYX-201 and PYX-203 programs," RTW says.
As part of the financing, RTW Investments LP's head of strategic investments, Gotham Makker, will join Pyxis' board of directors.
Makker says: "We are excited to co-lead this funding round. Under the leadership of its expert management team, Pyxis has developed a robust strategy for growth through its multiple biologics platforms, programs and strategic partnerships. We believe that the company will continue to execute its multi-asset multi-platform corporate strategy and quickly grow into an industry leader in oncology."
Current stock price: USD2.18
Year-to-date change: up 16%
By Paul McGowan; [email protected]
Copyright 2021 Alliance News Limited. All Rights Reserved.
Related Shares:
Rtw Biotech